Small cap robotic stock Adept Technology (NASDAQ: ADEP) has put in a very good performance this month verses its immediate peer�iRobot Corporation (NASDAQ: IRBT) as well as against medical robotic stocks like MAKO Surgical (NASDAQ: MAKO), Accuray Incorporated (NASDAQ: ARAY) and Hansen Medical, Inc (NASDAQ: HNSN). I should also mention that we have recently added Adept Technology to our SmallCap Network Elite Opportunity (SCN EO) portfolio (we are up 9% since last week) because we feel robotics is an improving sector as companies aim to reduce overhead and improve efficiencies through machine to machine (M2M) automation.What is Adept Technology?
Founded in 1983, small cap Adept Technology is the largest US based manufacturer of industrial robots. More specifically, Adept Technology�� product lines include industrial robots, configurable linear modules, machine controllers for robot mechanisms and other flexible automation equipment, machine vision, and systems and applications software. In addition, the company�provides specialized, cost-effective robotics systems and services to high-growth markets including Packaged Goods, Life Sciences, Disk Drive/Electronics and Semiconductor/Solar plus to�traditional industrial markets�which include�machine tool automation and automotive components.
10 Best Industrial Disributor Stocks To Watch For 2016: Momenta Pharmaceuticals Inc.(MNTA)
Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the characterization and process engineering of complex molecules. These complex molecules include proteins; polypeptides; and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development and commercialization of generic versions of complex drug products, as well as for the discovery and development of novel drugs. It offers Enoxaparin sodium injection, a generic version of Lovenox to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes. The company?s products also include M356, an abbreviated new drug application under FDA review, is a generic version of Copaxone for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; M118, which completed a Phase IIa clinical trial as an anticoagulant for acute coronary syndromes; and M402, a novel HSPG-based product candidate that is in preclinical development as a potential anti-cancer agent. It has collaboration agreements with Sandoz AG and Sandoz Inc. to develop and commercialize Enoxaparin sodium injection. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.Advisors' Opinion:
- [By Dan Caplinger]
Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more encouraging assessment of how long interest rates might remain low in order to stimulate and sustain economic growth, stocks climbed sharply, with the Dow posting triple-digit gains. Yet for MannKind (NASDAQ: MNKD ) , Momenta Pharmaceuticals (NASDAQ: MNTA ) , and Idera Pharmaceuticals (NASDAQ: IDRA ) , the news today was far from good, as all three stocks suffered declines of 10% or more.
- [By Maxx Chatsko]
Shares of biotech innovator Momenta Pharmaceuticals (NASDAQ: MNTA ) entered into a nosedive in early June, but quickly recovered after analysts at UBS AG upgraded the stock from "neutral" to "buy." I don't put any faith in analyst projections -- and neither should you -- but I do see value in the company's technology. Momenta has developed a platform for analyzing and characterizing complex molecules that could significantly reduce R&D costs and development times of drugs in the pipeline. If you're an investor looking for a biotech company with boatloads of potential, you may be wondering about adding Momenta to your portfolio. Fool contributor Maxx Chatsko breaks down that decision for investors in the following video.
- [By Maxx Chatsko]
It may not seem too impressive on the surface, but Momenta Pharmaceuticals (NASDAQ: MNTA ) has the makings of a game-changing biotech company. The company has developed a novel platform that greatly speeds the development and characterization of complex biological compounds. Unlike more traditional small molecules, therapeutic proteins are massive molecules whose exact chemical structure and makeup can vary from one production method to the other. Simple folds of subunits within the protein can drastically affect its efficacy and toxicity.
- [By James Brumley]
Just bear in mind this is largely an all-or-nothing bet on the drug, though PRAN stock could rally nicely leading up to its D-Day approval.Momenta Pharmaceuticals (MNTA)
Like Sagent Pharmaceuticals, Momenta Pharmaceuticals (MNTA) is a generic drugmaker. And also like Sagent, priced at $16.14 per share, MNTA stock is easily put into the cheap stocks category.
Top Life Sciences Stocks To Buy Right Now: John Wiley & Sons Inc (JW.A)
John Wiley & Sons, Inc., incorporated on January 15, 1904, is a global provider of knowledge and knowledge-based services in areas of research, professional development and education. Core businesses produce scientific, technical, medical and scholarly research journals, reference works, books, database services, and advertising; professional books and certification, assessment and training services, and education content and services, including online program management for colleges and universities and integrated online teaching and learning resources for instructors and students. The Company sells its products to customers in the Middle East (including Iran and Syria), Africa (including Sudan), Cuba, and other developing markets where it does not have operating subsidiaries.
The Company�� Research business serves the world�� research and scholarly communities and is a publisher for professional and scholarly societies. Research�� mission is to support researchers, professionals and learners in the discovery and use of research knowledge to achieve results that help shape the future. Research products include scientific, technical, medical and scholarly research journals, books, major reference works, databases, clinical decision support tools and laboratory manuals and workflow tools, in the publishing areas of the physical sciences and engineering, health sciences, social science and humanities and life sciences. Research customers include academic, corporate, government, and public libraries; researchers; scientists; clinicians; engineers and technologists; scholarly and professional societies, and students and professors. The Company�� Research products are sold and distributed globally, online and in print through multiple channels, including research libraries and library consortia, independent subscription agents, direct sales to professional society members, bookstores, online booksellers and other customers. Publishing centers include Australia, Ge! rmany, India, Singapore, the United Kingdom and the United States. Research accounted for approximately 57% of total Company revenue (fiscal 2013). The Company�� Research business is a provider of content and services in evidence-based medicine (EBM). Through the Company�� alliance with The Cochrane Collaboration, the Company publishes The Cochrane Library.
Wiley Online Library, the online publishing platform for the Company�� Research business, is a multidisciplinary collections of online resources covering life, health and physical sciences, social science and the humanities. Wiley Online Library delivers seamless integrated access to over four million articles from 1,500 journals, 13,000 online books, and hundreds of reference works, laboratory protocols and databases. Wiley Online Library provides the user with intuitive navigation, enhanced discoverability, expanded functionality and a range of personalization options. Wiley Open Access is the Company�� publishing program for open-access research articles. Under the Wiley Open Access business model, research articles submitted by authors are published and compiled by subject area into open-access journals. In addition to Wiley Open Access, the Company provides authors with the opportunity to make their individual research articles that were published within the Company�� paid subscription journals freely available to the general public through OnlineOpen.
Professional Development (PD)
The Company�� Professional Development business acquires, develops and publishes professional books, subscription products, certification and training services and online applications in the areas of business, finance, accounting, workplace learning, management, leadership, technology, behavioral health, engineering/ architecture and education. Products are developed in print and digitally for worldwide distribution through multiple channels, including major chains and online booksellers, independent bookstores, libr! aries, co! lleges and universities, warehouse clubs, corporations, direct to consumer, websites and other online applications. Publishing centers include Australia, Canada, Germany, India, Singapore, the United Kingdom and the United States. Professional Development accounted for approximately 24% of total Company revenue in fiscal year 2013. Professional Development revenue by product type includes eBooks and Print Books; Online Training and Assessment which is revenue from the sale of products and services focusing on workplace effectiveness and career success; Publishing Rights which is revenue from the licensing of the right to republish Wiley content either online or in print; Journal Subscriptions online and in print to professionals, and Other.
The Company�� Education business produces educational content and services, including online program management for colleges and universities and integrated online teaching and learning resources for instructors and students. Education�� mission is to help teachers teach and students learn by delivering to students, faculty and institutions throughout the world personalized content, tools and services that demonstrate results. Education offers products and services principally delivered through college bookstores and online distributors, with customers having access to content in multi-media formats, as well as the traditional textbook. Education�� solutions are available in each of its publishing disciplines, including the sciences, engineering, computer science, mathematics, business and accounting, statistics, geography, hospitality and the culinary arts, education, psychology and modern languages. Education accounted for approximately 19% of total Company revenue in fiscal year 2013. Education revenue by product type includes eBooks and Print Textbooks; Online Program Management; WileyPLUS, the Company�� online learning solution; revenue from the licensing of publishing content rights and Other Nontraditional and Digita! l Product! s, such as custom publishing and other content adaption��.
Education offers online learning solutions including WileyPLUS, it�� research-based, online environment for effective course teaching and learning that is integrated with a complete digital textbook. WileyPLUS improves student learning through instant feedback, personalized learning plans, and self- evaluation tools and a range of course-oriented activities, including online planning, presentations, study, homework and testing. The Company also provides the services of the Wiley Faculty Network, a global community of faculty that offers guidance, training, and resources. Through the Wiley Faculty Network, instructors and administrators can collaborate with each other, attend virtual and live events, and utilize a wealth of resources all designed to help them grow as educators.
The Company publishes approximately 1,600 Research and Professional Development journals. Journal subscription revenue and other related publishing income, such as advertising, backfile sales, the licensing of publishing rights, journal reprints and individual article sales accounted for approximately 48% of the Company�� consolidated fiscal year 2013 revenue. The journal portfolio includes titles owned by the Company, in which case they may or may not be sponsored by a professional society; titles owned jointly with a professional society; and titles owned by professional societies and published by the Company pursuant to long-term contracts. The Company also enters into agreements with outside independent editors of journals that state the duties of the editors, and the fees and expenses for their services. The Company sells journal subscriptions directly through Company sales representatives; indirectly through independent subscription agents; through promotional campaigns, and through memberships in professional societies for those journals that are sponsored by societies. Journal subscriptions are primarily! licensed! through contracts for online content delivered through the Company�� online platform, Wiley Online Library.
The Company�� Book products and book related publishing revenue, such as advertising and the sale of publishing rights, accounted for approximately 48% of the Company�� fiscal year 2013 revenue. The Company enters into agreements with authors that state the terms and conditions under which the materials will be published, the name in which the copyright will be registered, the basis for any royalties, and other matters. The Company develops content in a digital format that can be used for online and print products, resulting in productivity and efficiency savings, and enabling print-on-demand delivery. Book content is available online through Wiley Online Library, WileyPLUS, Custom Select and other platforms. Ebooks are delivered to intermediaries, including Amazon, Apple and Google for re-sale to individuals in various industry-standard formats, which are now also the preferred deliverable for licensees of all types, including foreign language publishers.
Other Digital Products and Services
The Company is focused on delivering content-enabled services which improve learning, career management and effectiveness for its target communities. The Inscape and ELS businesses, along with the Company�� Pfeiffer brand, represent the Company�� professional training and assessment services. These businesses offer a variety of classroom learning solutions and e-learning activities that are delivered to customers directly through online digital delivery platforms and also through an authorized distributor network of independent consultants, trainers and coaches. The Company�� professional training and assessment services offer highly flexible packages and modules for its customers that include online pre-work and profile assessments, self-study materials, online videos, mobile apps and other sophisticated planning tools.The Com! pany generates advertising revenue from print and online journal subscription products; its online publishing platform, Wiley Online Library; the Wiley Job Network, a full service online job board; online events such as webinars and virtual conferences; community interest websites such as spectroscopyNOW.com and websites for the Company�� brands like Dummies.com. The Company�� publications and services are sold throughout most of the world through operations located in Europe, Canada, Australia, Asia, and the United States. Advisors' Opinion:
- [By Arie Goren]
After running this screen on May 21, 2013, before the markets' open, I discovered the following eight stocks: Sunoco Logistics Partners LP (SXL), Leggett & Platt Inc (LEG), Copa Holdings SA (CPA), RPC Inc. (RES), Tupperware Brands Corp. (TUP), Herbalife Ltd. (HLF), John Wiley & Sons Inc. (JW.A) and C.H. Robinson Worldwide Inc. (CHRW).
- [By Geoff Gannon]
Here, you want to compare the return on the company's buyback with the return you could achieve. However, you want to keep in mind that while you would pay a tax on the dividend the company does not pay a tax on the buyback. Let's say I imagine John Wiley (JW.A) will get a 10% return on its buyback. Likewise, I think I can go out and return 10% a year myself picking my own stocks. In this case, which should I prefer? Should I prefer John Wiley paid a dividend or used all of its free cash flow to buyback stock?
- [By Geoff Gannon]
John Wiley (JW.A)
Notice that 4 of those 10 stocks have a market cap under $100 million. This is shocking. I�� ranking the companies by years of positive earnings (special items ��which explain H&R Block�� losses ��are excluded). If a company earns money for several decades ��this group has tended to be profitable for over 30 years ��and it retains that money, it will end up with a big market cap.
Top Life Sciences Stocks To Buy Right Now: Zogenix Inc (ZGNX)
Zogenix, Inc. (Zogenix), incorporated on May 11, 2006, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company�� product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. Sumavel DosePro and Zohydro are used for the treatment options available to patients and physicians in the United States. Sumavel DosePro may serve as a treatment alternative to oral and nasal triptans and offers administration when compared to traditional, needle-based sumatriptan injection. In May, 2012, it submitted a New Drug Application to the Food and Drug Administration (FDA).
The Company�� collaboration with Astellas has been terminated on March 31, 2012. Sumavel DosePro is a pre-filled, single-use disposable, needle-free drug delivery system that subcutaneously delivers 6 mg of sumatriptan in 0.5 mL of sterile liquid. Sumavel DosePro is designed to be portable, intuitive and easy-to-use. To use, the patient simply snaps off a plastic tip, flips back a lever and presses the end of the delivery system to the skin of the abdomen or thigh. Under the force of a small amount of compressed nitrogen gas, the liquid form of sumatriptan is expelled out of the device as a thin jet of medication, which pierces the skin and selectively deposits into the subcutaneous tissue.
Zogenix competes with GlaxoSmithKline, AstraZeneca PLC, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., ! Inc., Pfizer Inc., Alexza Pharmaceuticals, Inc., MAP Pharmaceuticals, Inc., Abbott Laboratories, Alpharma Inc., Endo Pharmaceuticals Holdings Inc., King Pharmaceuticals, Inc., Mallinckrodt Inc., Purdue Pharma L.P., Teva Pharmaceutical Industries Limited, Watson Pharmaceuticals, Inc., Becton, Dickinson and Company, Owen Mumford Ltd., Ypsomed, Sandoz Inc., Bioject Inc. and Antares Pharma Inc.Advisors' Opinion:
- [By Sean Williams]
What: Shares of Zogenix (NASDAQ: ZGNX ) , a biopharmaceutical company developing therapies to treat central nervous system disorders and pain, jumped as much as 15% after updating the status of its severe pain medication Zohydro ER in Massachusetts.
Top Life Sciences Stocks To Buy Right Now: Fortescue Metals Group Ltd (FSUMF)Fortescue Metals Group Limited (Fortescue) is an iron ore producer and explorer operating in the Pilbara region of Western Australia. Fortescue is engaged in mining of iron ore from its Cloudbreak and Christmas Creek mine sites, the operation of an integrated mine, rail and port supply chain and the expansion of iron ore operations. Its Cloudbreak mine site is located in the Chichester Ranges in the Pilbara region of Western Australia, 263 kilometers (km) south of Port Hedland and 150km north of Newman. Its Christmas Creek is second mining operation, 50 km to the east of Cloudbreak. The Company has also designed and constructed rail and port facilities to support the development and sale of the Pilbara's stranded iron ore bodies. Its subsidiaries include The Pilbara Infrastructure Pty Limited, FMG Pilbara Pty Limited, Chichester Metals Pty Limited, Pilbara Mining Alliance Pty Limited, and Karribi Developments Pty Limited. Advisors' Opinion:
- [By MARKETWATCH]
LOS ANGELES (MarketWatch) -- Australian stocks rallied in early Monday trade, with the S&P/ASX 200 (AU:XJO) adding 0.9% to 5,433.50 to hit another five-year high after Wall Street booked gains Friday. Miners were a strong spot, with Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) up 2.3%, BHP Billiton Ltd. (AU:BHP) (BHP) gaining 0.9%, Evolution Mining Ltd. (AU:EVN) (CAHPF) ahead by 2.6%, and Rio Tinto Ltd. (AU:RIO) (RIO) rising 1.1% after selling its interest in eastern Australia's Clermont coal mine for about $1 billion. Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) improved by 1.4%, the best performer among the major banks, after an Australian Financial Review reported David Gonski, executive chairman of the Australian government's Future Fund, was being sought to run the lender.
Top Life Sciences Stocks To Buy Right Now: Walter Energy Inc.(WLT)
Walter Energy, Inc. produces and exports metallurgical coal for the steel industry primarily in the United States. The company also produces thermal and industrial coal, anthracite, metallurgical coke, coal bed methane gas, and other related products. It principally serves electric utility and industrial customers. The company was formerly known as Walter Industries, Inc. and changed its name to Walter Energy, Inc. in April 2009. Walter Energy, Inc. was founded in 1946 and is headquartered in Birmingham, Alabama.Advisors' Opinion:
- [By John Kell and Tess Stynes var popups = dojo.query(".socialByline .popC"); p]
Walter Energy(WLT) doubled the size of its five-year 9.5% senior secured note sale to $200 million, along with the sale of $350 million in second lien PIK toggle notes due in 2020. PIK toggle notes give the issuer an option to pay interest with new debt instead of cash. Walter Energy will pay off part of an existing credit facility with the bond proceeds as it aims to extend the maturity of its debt burden with the hope that coal prices will rebound and return the company to profitability. Shares fell 12% to $7.98 premarket.
Top Life Sciences Stocks To Buy Right Now: SL Green Realty Corporation(SLG)
SL Green Realty Corp. is a real estate investment trust (REIT). The firm engages in the property management, acquisitions, financing, development, construction, and leasing. It also provides tenant services to its clients. The firm invests in real estate markets of the United States. It primarily invests in commercial office and retail properties. SL Green Realty Corp. was founded in 1970 and is based in New York, New York.Advisors' Opinion:
- [By Marc Bastow]
Property management, financing and construction real estate investment trust (REIT) SL Green (SLG) raised its quarterly dividend 51.5% to 50 cents per share, payable on Jan. 15 to shareholders of record as of Dec. 31.
SLG Dividend Yield: 2.2%
- [By Marc Bastow]
Property management and financing real estate investment trust SL Green Realty (SLG) raised its quarterly dividend 52% to 50 cents per share. SLG did not release a payment or ex-dividend date for the new dividend.
SLG Dividend Yield:�2.04%